Sodium,Micafungin,Pneumocandins

Pneumocandins

 

 

Amphotericin B,1397-89-3
Amphotericin B
Amphotericin B,1397-89-3
CAS
1397-89-3
Molecular Formula
C47-H73-N-O17
Molecular Weight
924.08
Systematic Name
Amphotericin B
Certificate of analysis
Amphotericin B,1397-89-3
View via PDF file
Amphotericin B,1397-89-3
Specification
Appearance
Yellow to orange powder.
Complies
Solubility
Insoluble in water and in ether,slightly soluble in methanol
Conforms
Identification
A:(UV)
Conforms to standard, absorbance in the
range of 240nm to 320nm
Conforms
Identification
B:(UV/Vis)
Conforms to standard, absorbance
in the range of 320nm to 400nm
Conforms
Loss on drying
Not more than 5.0%
2.7%
Residue on Ignition
Not more than 3.0%
1.1%
Limit of
Amphotericin A
Not more than 15%
Not detected
Assay( Microbial)
Not less than 750ug/mg calculated on the
dried basis
952ug/mg
Microbial limits
Total Aerobic count: Not more than
100CFU/ gram
Salmonella species: Negative
Eschenchia Coli: Negative
0CFU/gram
Conforms
Conforms
Residual Solvents
Ethanol : Not more than 5000ppm
Acetone: Not more than 5000ppm
2777ppm
1311ppm
Contact us for more information
Chemical information
Compound Name*
CAS No. "N/A" if the CAS not available*
Quantity*
Contact information
Contact person*
Email Address *
Tel No.*
Company or Organization Name*
Shipping Address*
Country
Remarks

<Privacy policy: the contact information will be only used for this business contact>

Related Pneumocandins
Patent Disclaimer
PD1
Products protected by valid patents are not offered for sale in jurisdictions where the sale of such products constitutes a patent infringement. The current list only reflects the products and technologies that are available, under development: note that some products may be developed or produced for internal and experimental uses with no commercal aim.
PD2
Sales of products are limited to those allowed by Chapter VII PLPRC 63, the above includes Research and development quantities.
PD3
the buyer assumes responsibility of all patent considerations in the use of
Lano ’s Pharmaceutical Co.,Ltd product(Amphotericin B,1397-89-3).
PD4
R&D use in accordance with (1) 35 USC 271(e)+A13(1) in the U.S.; (2) Section 69.1 of Japanese Patent Law in Japan; (3) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (4) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (5) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (6) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (7) such similar laws and rules as may apply in various other countries.